HighLife (Paris) recently announced it raised €80 million (more than $90 million U.S.) for a U.S. pivotal study and expanded European commercialization of its TMVR system. The successfully completed fundraise, announced Sept. 22, was co-led by Andera Partners, Sofinnova Partners, Supernova Invest and Mérieux Equity Partners. Other new investors … [Read more...] about HighLife raises more than $90M to advance its TMVR system
HighLife SAS
Peijia Medical seeks CE mark for its TEER system
Peijia Medical (Suzhou, China) announced today that it has submitted to receive a CE mark for its GeminiOne transcatheter edge-to-edge repair (TEER) system to treat mitral regurgitation. Paris-based HighLife, which recently secured a CE mark for its transcatheter mitral valve replacement (TMVR) system, is Peijia Medical's European partner in the … [Read more...] about Peijia Medical seeks CE mark for its TEER system
HighLife unveils new large annular valve for mitral regurgitation clinical trials
HighLife SAS announced this week that it introduced a new valve size in its clinical trials for treating mitral regurgitation (MR) in larger anatomies. Paris-based HighLife’s latest trans-septal mitral valve replacement (TSMVR) is a large annulus valve (LAV). The company designed it to fit within its existing delivery catheter and to accommodate … [Read more...] about HighLife unveils new large annular valve for mitral regurgitation clinical trials
